Synthesis of hepatitis B virus e antigen in E. coli

Area of Science:

• Molecular Biology
• Virology
• Biotechnology

Background:

• Hepatitis B virus (HBV) infection is a significant global health concern.
• Understanding the antigenicity of HBV core antigen (HBcAg) and HBeAg is crucial for vaccine development and diagnostics.
• Current methods for producing HBV antigens have limitations.

Purpose of the Study:

• To engineer E. coli to express functional Hepatitis B virus core antigen (HBcAg) and HBeAg.
• To investigate the antigenicity and stability of the expressed HBV antigens.
• To explore the potential for producing novel HBV antigen variants.

Main Methods:

• Deletion and insertion of the HBcAg gene into E. coli expression plasmids containing the tryptophan promoter.
• Transformation of E. coli with engineered plasmids.
• Analysis of synthesized materials for HBcAg and HBeAg antigenicity.
• Characterization of the size and stability of produced HBeAg-specific material.

Main Results:

• E. coli transformants successfully synthesized materials exhibiting HBcAg, HBeAg, or dual antigenicity.
• A stable, smaller form of HBeAg-specific material was produced, distinct from the native HBeAg.
• The genetic modifications allowed for diverse antigen expression profiles.

Conclusions:

• Engineered E. coli can serve as a platform for producing various Hepatitis B virus antigens.
• The successful production of a smaller, stable HBeAg variant offers new possibilities for research and therapeutic development.
• This approach provides a flexible method for generating HBV antigens with distinct antigenic properties.